BioArctic says it has dosed the first patient with exidavnemab in the EXIST Phase IIa study in Parkinson’s disease patients.  

Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role in the disease progression in different neurological disorders including Parkinson’s disease. 

The Phase IIa study EXIST (EXIdavnemab Synucleinopathy Trial) will be conducted in Europe and at least 24 patients will be recruited. 

Patients will be divided into two cohorts of 12 (Cohort 1 and Cohort 2). Participants in Cohort 1 will receive either a lower dose of exidavnemab or placebo and participants in Cohort 2 will receive either a higher dose of exidavnemab or placebo. 

“We are very excited that the first patient with Parkinson’s disease has now been dosed in the EXIST Phase IIa study with exidavnemab,” said Gunilla Osswald, CEO at BioArctic. “It marks an important next step on BioArctic’s pioneering journey to broaden our research portfolio and help more patients and families with different neurological disorders to a better life.” 

The results of two separate Phase I studies of exidavnemab, conducted in collaboration with AbbVie, have shown that exidavnemab is generally well-tolerated, with an excellent half-life of approximately 30 days.  

These data together with the high affinity and selectivity toward the pathological aggregated forms of α-synuclein, key to maintaining a high target binding in the brain, laid the foundation for the Phase IIa study. 

BioArctic invented Leqembi (lecanemab), which was developed together with Eisai, who is responsible for regulatory interactions and commercialisation globally. In addition to Leqembi, BioArctic has a research portfolio with antibodies against Parkinson’s disease and ALS as well as additional projects against Alzheimer’s disease.

Diana Spencer, Senior Digital Content Editor, DDW